#USA #New York #Class Action #securities lawsuit #ADMA Biologics

Investors Warned About ADMA Biologics, Inc. Class Action Deadline

On July 16, 2026, SueWallSt issued a crucial alert to investors regarding ADMA Biologics, Inc. (NASDAQ: ADMA), emphasizing a forthcoming securities class action deadline. This alert serves as a warning for shareholders who may be eligible to recover their losses due to alleged financial discrepancies within the company. The notable class period for this lawsuit spans from August 9, 2024, to March 25, 2026.

Background and Allegations

Recently, the spotlight has shifted to ADMA due to serious allegations claiming that the biopharmaceutical company misrepresented the effectiveness of its internal controls over financial reporting. A March 2026 research report raised eyebrows by suggesting that instead of the reported 20% revenue growth, the actual growth could be a staggering negative 3%. This revelation has significant implications for the credibility of ADMA's financial statements and processes.

Key Findings of the Class Action

The lawsuit is rooted in several critical findings, including:

• - Misleading Certifications: ADMA's management allegedly certified their internal controls as effective over seven consecutive SEC filings during the class period. However, these certifications are claimed to be materially false due to the company engaging in channel stuffing practices and concealing a transaction with a related party.
• - Undisclosed Transactions: The action points out that ADMA disclosed purchases from a related party, but omitted crucial sales to a separate entity that allegedly operated from the same headquarters, thereby masking the true nature of their financial dealings. The two entities reportedly share ownership ties, further complicating matters.
• - ASCENIV Revenue Issues: Additionally, the class action highlights that ADMA's financial filings suggested product revenue was recognized at the point when customers gained control. However, it argues that the company shipped surplus ASCENIV products to distributors to create a fictitious demand.

Implications for Investors

Joseph E. Levi, Esq., representing the plaintiffs, emphasizes that when a corporation certifies its internal controls while allegedly concealing critical revenue information, it denies investors the transparency they need to make informed decisions. This lack of clarity and control failure directly impacts investors' trust and potentially their financial safety.

Next Steps for ADMA Investors

For ADMA investors, it is vital to understand the potential eligibility for joining this class action. If investors purchased ADMA securities during the class period and faced financial losses, they may qualify to participate. It's important to gather brokerage records showcasing purchase dates and volumes.

1. Gather Documents: Investors should compile their transaction records to substantiate claims of financial loss.
2. Contact Legal Representatives: Those interested in exploring their options can reach out to SueWallSt for a free case evaluation, ensuring no immediate action is required to remain an eligible class member.
3. Understand the Costs: Participation in the lawsuit is at no upfront cost, as securities class actions operate on a contingency basis.

Conclusion

As the deadline for appointing a lead plaintiff approaches on August 10, 2026, affected ADMA investors are urged to act promptly. This case stands as a reminder of the significance of transparency in the corporate financial ecosystem and the potential risks investors face when such principles are not upheld.

For more detailed information regarding the case or to assess eligibility, ADMA investors should reach out confidently.

Contact Information

For inquiries, please contact:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Email: [email protected]
Phone: (888) SueWallSt